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ciliaMutations in the human gene ALMS1 cause Alström syndrome, a disorder characterised by neurosensory
degeneration, metabolic defects and cardiomyopathy. ALMS1 encodes a centrosomal protein implicated in
the assembly and maintenance of primary cilia. Expression of ALMS1 varies between tissues and recent data
suggest that its transcription is modulated during adipogenesis and growth arrest. However the ALMS1
promoter has not been deﬁned. This study focused on identifying and characterising the ALMS1 proximal
promoter, initially by using 5' RACE to map transcription start sites. Luciferase reporter assay and EMSA data
strongly suggest that ALMS1 transcription is regulated by the ubiquitous factor Sp1. In addition, reporter
assay, EMSA, chromatin immunoprecipitation and RNA interference data indicate that ALMS1 transcription is
regulated by regulatory factor X (RFX) proteins. These transcription factors are cell-type restricted in their
expression proﬁle and known to regulate genes of the ciliogenic pathway. We show binding of RFX proteins
to an evolutionarily conserved X-box in the ALMS1 proximal promoter and present evidence that these
proteins are responsible for ALMS1 transcription during growth arrest induced by low serum conditions. In
summary, this work provides the ﬁrst data on transcription factors regulating general and context-speciﬁc
transcription of the disease-associated gene ALMS1.n; cDNA, DNA complementary
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Alström syndrome is a rare genetic disorder characterised by
retinal dystrophy, childhood obesity, type 2 diabetes and sensorineu-
ral hearing loss, with other common features including dilated car-
diomyopathy and hepatic and renal failure (Alstrom et al., 1959;
Marshall et al., 2005). Alström syndrome is caused by mutations in a
novel gene, ALMS1 (Collin et al., 2002; Hearn et al., 2002), which
encodes a centrosomal protein (Andersen et al., 2003; Hearn et al.,2005). Recent data indicate that ALMS1 is required for the proper
formation and/or maintenance of primary cilia (Graser et al., 2007; Li
et al., 2007), sensory cell-surface organelles whose dysfunction is
implicated in the pathogenesis of a number of human genetic dis-
orders (Ansley et al., 2003; Badano et al., 2006).
Although ALMS1 is widely expressed (Collin et al., 2005; Hearn
et al., 2005), northern blot analysis shows evidence of variation in
expression level between tissues, with particularly high detection
in testis (Collin et al., 2002; Hearn et al., 2002). Spatially restricted
expression has been reported in mouse olfactory epithelium (Genter
et al., 2003) and recent studies using cellular models indicate that
ALMS1 mRNA levels are upregulated in response to serum starvation
(Yabuta et al., 2006) and downregulated during adipogenesis (Romano
et al., 2008). Alterations in transcription are likely to contribute to these
changes in mRNA abundance, however the promoter of ALMS1 has not
been characterised and therefore the mechanisms controlling ALMS1
transcription are unknown.
We previously deﬁned the exon/intron structure of ALMS1 by
RT-PCR using primers in predicted exons, and RACE (Hearn et al.,
2002). This approach indicated a larger gene than previously pre-
dicted, with 23 exons and a 12.9-kb mRNA, and broadly placed the
putative start of transcription within a CpG island. Here, we have
discovered and precisely mapped variable transcriptional start sites
(TSSs) for ALMS1. We have deﬁned a minimal promoter region and
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scription under generalised and speciﬁc conditions respectively.
2. Materials and methods
2.1. Rapid ampliﬁcation of cDNA ends (RACE)
PCRs were performed on Firstchoice Race-Ready cDNA (Ambion)
derived from adult human pancreas, liver and testes. We used 5' RACE
Outer and Inner forward primers corresponding to the 5' RACE adapter
sequence (Ambion), in combination with an ALMS1-speciﬁc reverse
primer spanning the exon 4/5 junction (5'-aggaattcccctcagaggtgcaaaact-
tag-3') and a nested reverse primer in exon 4 (5'-caaattcttggtcttgtgt-
caaac-3') respectively. Nested PCR products were gel extracted and
cloned using a BamHI site in the 5' RACE Inner primer and a BglII site in
exon 3 of ALMS1. Ten to thirteen clones were sequenced for each tissue.
2.2. DNA sequence alignment
Genomic sequences upstream of ALMS1 orthologues were aligned
with human genomic sequence using ClustalW within Lasergene
software (DNASTAR, Inc.), with default parameters.
2.3. ALMS1 promoter constructs
Base pairs −412 to +36 (relative to the liver transcription start
site deﬁned here by RACE) were ampliﬁed by PCR from genomic
DNA using restriction site-tagged primers and cloned in pGL3-Basic
(Promega) using KpnI and BglII. Deletion constructs were cloned by
PCR using this construct as template. Point mutations (Fig. 3A) were
introduced into construct −232/+36 using a PCR based method. All
constructs were veriﬁed by sequencing.
2.4. Cell culture, transfection and reporter assays
Cells were maintained in Dulbecco's modiﬁed Eagle medium
supplemented with 10% fetal calf serum (FCS) and antibiotics at 37 °C
and 5% CO2 (reagents from PAA Laboratories). PANC-l and HepG2
cells were seeded in 12-well culture plates (1×105 cells/well) and
transiently transfected using TransFast reagent (Promega). Transfec-
tions were performed in triplicate. One hour post-transfection, 1 ml
DMEM 10% FCSwas added and cells incubated for 4 h. Growthmedium
was then replacedwithmedium containing either 10% or 0.5% FCS. Cells
were lysed 48 h later in 1×Passive Lysis Buffer (Promega) and luciferase
expression quantiﬁed using the Luciferase Reporter Assay System
(Promega) with a TD-20/20 luminometer (Turner Biosystems). Each
experiment was performed at least three times, in triplicate. Signiﬁcant
reductions in luciferase activity were veriﬁed by using at least two
independent preparations of the relevant plasmids.
2.5. Immunoﬂuorescence microscopy
PANC-1 cells were seeded in chamber slides (VWR International)
and incubated in medium containing 10% or 0.5% FCS for 72 h. To
allow clear visualization of primary cilia, prior to ﬁxation cells were
incubated on ice for 50 min to depolymerise cytoplasmic micro-
tubules. Cells were ﬁxed in chilled methanol for 5 min. Immunoﬂu-
orescence microscopy was performed as described (Hearn et al.,
2005), using mouse anti-acetylated tubulin antibody (1:2000; Sigma-
Aldrich). Cells were mounted in Vectashield containing DAPI (Vector
Laboratories).
2.6. In vitro transcription/translation
pCDNA3-Flag-RFX1 was kindly provided by Zijie Sun, Stanford
University (Iwama et al., 1999). In vitro transcription/translationwas performed using the T7 TNT Quick Coupled Translation System
(Promega). Protein expression was veriﬁed by SDS-PAGE and immu-
noblotting as described (Hearn et al., 2005), using goat anti-RFX1 (Santa
Cruz Biotechnology) and peroxidase-conjugated anti-goat (Sigma-
Aldrich) antibodies.
2.7. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described (Schreiber et al.,
1989). Synthetic oligonucleotides (Qiagen) were annealed and end-
labelled with [γ-32P]dCTP. Point mutations designed to disrupt
transcription factor binding sites are shown in Fig. 3A. Nuclear extract
(4 μg) was incubated in reaction mixture (10 mM Tris–HCl pH 7.5,
1 mM MgCl2, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol,
and 0.05 mg/ml poly dI–dC) for 15 min at room temperature. For
supershift assays, nuclear extracts were pre-incubated on ice for 1 h
with 2 µg anti-RFX1 or anti-RFX2 antibody (Santa Cruz Biotechnol-
ogy). Following addition of radiolabelled probe, reaction mixtures
were incubated at 37 °C for 30 min. The resulting protein/DNA com-
plexes were resolved by electrophoresis on non-denaturing 4%
polyacrylamide gels in 0.5× TBE buffer. Gels were then dried and
exposed to X-ray ﬁlm.
2.8. Chromatin immunoprecipitation (ChIP)
PANC-1 cells were incubated in DMEM containing 0.5% FCS for 48 h.
ChIP was performed with goat anti-RFX1, anti-RFX2, IgG (Santa Cruz
Biotechnology) or no antibody. Themethodwas essentially as described
(Sanchez-Elsner et al., 2004), except that Protein G-agarose beads (GE
Healthcare) were used, and Protein G agarose/antibody/protein
complexes were washed as follows: four washes with lysis buffer
(25 mMTris–HCl pH 7.5, 140 mMNaCl, 1 mMEDTA, 1% (v/v) Triton-X-
100, 0.1% (w/v) SDS); fourwashes with lysis buffer containing 500 mM
NaCl; four washes with IP wash solution (10 mM Tris–HCl pH 8.0,
250 mMLiCl, 0.5% (v/v) NP-40, 0.5% (w/v) sodiumdeoxycholate, 1 mM
EDTA); and fourwasheswith TE (pH8.0). RecoveredDNAwasampliﬁed
with custom Taqman Assays (Applied Biosystems) spanning a 90-bp
region encompassing the X-box of the ALMS1 promoter (forward: 5'-
GCGGCGTCCCTAGCAA-3', reverse: 5'-CCCTGACTGGCGGTTGT-3', probe:
5'-CACTGCGCCTAAGCTG-3') and an 87 bp region upstream of GAPDH
(forward: 5'-CCTAATTATCAGGTCCAGGCTACAG-3', reverse: 5'-
CGGGAGGCGGCTTGA-3', probe: 5'-CTGCAGGACATCGTG-3'). Triplicate
qPCRs were performed using an ABI 7900HT Fast Real-Time
System (Applied Biosystems). Percentage of input was calculated as
100×2[Ct(input) – Ct(IP)], after adjusting the mean input Ct value for 1/5
starting material (fraction of input chromatin reserved).
2.9. RNA interference
PANC-1 cells were transfected with pools of three siRNA duplexes
targeting RFX1, 2 or 3 (Ambion) or siRNA targeting Lamin (Dharmacon)
at 5 nM using HiPerFect transfection reagent (Qiagen). Four hours later
growth medium was replaced with medium containing either 10% or
0.5% FCS. Cells were harvested 72 h post-transfection. For quantitative
reverse transcription-PCR analysis, total RNA was extracted using TRI
reagent (Sigma-Aldrich). RNA was treated with RNAse-free DNAseI
(Promega) prior to reverse transcription with oligo d(T)15 primer and
Superscript III (Invitrogen)according to themanufacturer's instructions.
The resulting cDNAs were ampliﬁed using pre-designed TaqMan Gene
Expression Assays (Applied Biosystems) and an ABI 7900HT System.
Assays were performed in triplicate and TBP was used as endogenous
control for relative quantiﬁcation. For immunoblot analysis, cells were
lysed in RIPA buffer (Sigma-Aldrich) supplemented with protease
inhibitors (Complete Mini; Roche) for 30 min on ice, and cell lysates
then centrifuged at 13,000 rpm for 10 min at 4 °C. Proteins were
separated by SDS-PAGE (40 µg/lane) and analysed by immunoblotting,
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Santa Cruz Biotechnology), peroxidase-conjugated anti-goat (1:50,000)
and peroxidase-conjugated anti-β-actin (1:50,000; Sigma-Aldrich)
antibodies.
3. Results
3.1. Transcription start site mapping
Our previous TSS prediction for ALMS1 was based on the presence
of a potential initiator element close to the most extreme 5' cDNA
sequence obtained by RT-PCR (Hearn et al., 2002; our unpublished
observations). This did not exclude the possibility that transcription
is initiated further upstream, either in contiguous sequence or at
undiscovered exon(s). Deﬁning the TSS of ALMS1 is therefore impor-
tant both to help identify the promoter and to resolve whether
additional exons lie upstream of the previously deﬁned exon 1. To
achieve this we performed 5'-RACE on cDNA generated from full-
length, capped mRNAs. We used cDNAs derived from human liver,
testes and pancreas, all of which express the ALMS1 gene (Collin et al.,
2002; Hearn et al., 2002). We cloned 10–13 RACE products for each
tissue and compared their sequences to the publically available
human genome sequence to identify putative TSSs. All of the
sequences obtained began within a 48-bp region overlapping the
previously predicted start of exon 1 (Fig. 1). All sequences were
continuous with the genome from their 5'-ends to the splice donor
site of exon 1, i.e. they provided no evidence of novel exons. Notably,
all ten liver-derived sequences started at the same nucleotide (Fig. 1),
hereinafter used as a reference and termed position +1. Six out of
thirteen testis-derived sequences also started at position +1, while
others started at positions −19, +10, +19 and +20 (Fig. 1). In
contrast to both the liver and testis clones, all ten pancreas-derived
sequences started at position +29. Notably, all transcripts are pre-
dicted to utilise the previously identiﬁed methionine start codon at
position +101. In summary, these data suggest multiple and possibly
tissue-speciﬁc TSSs for exon 1.
We compared our results with data from the cap-analysis of gene
expression (CAGE) database, a transcriptome-wide analysis of
sequenced capped 5' ends of transcripts, termed CAGE tags (Shiraki
et al., 2003; Kawaji et al., 2006). Of the 143 CAGE tags mapped to
ALMS1, 77 were dispersed at 63 different positions throughout the
gene. These scattered CAGE tags may represent post-transcriptional
processing events (exonic tags; Fejes-Toth et al., 2009) or artefacts
rather than TSSs, and therefore we focused our attention on larger
clusters of tags. Notably, the most extreme 5' cluster of more than two
tags (bp−43 to+20; 24 tags) overlapped the TSS region identiﬁed by
RACE (bp −19 to +29) and suggested a broad TSS distribution
(Fig. 1). The most common start site in the cluster, position−21, was
supported by six tags, ﬁve of which were from a skin cell line; other
tags in the cluster were derived from intestine, cerebrum, cecum andFig. 1. Transcription start site mapping data. Summary of ALMS1 transcription start sites su
analysis of gene expression (CAGE) database (Kawaji et al., 2006). Only the most extreme 5
relative to the liver TSS predicted by RACE; y-axis, cumulative total of RACE clones/CAGE tag
2002). The predicted translation start codon of ALMS1 is at position +101 (not shown).adipose. There were two nearby clusters of CAGE tags, at bp +71
to +95 (32 tags) and bp +259 to +305 (10 tags), suggesting
alternative promoters in exon 1. However, we did not ﬁnd evidence of
TSSs in either region by RACE.
3.2. Genomic context of putative transcription start sites
In silico (MatInspector) analyses of genomic sequence upstream
of the TSSs deﬁned by 5'-RACE failed to identify a TATA box. To aid
discovery of cis-acting regulatory elements we aligned bp −1000 to
+100 of the human genomic sequence with corresponding sequences
from dog,mouse and rat. This revealed several evolutionarily conserved
regions between bp −200 and +100, but less conservation further
upstream (Fig. 2A and data not shown). Notably, the region −1000 to
−394 is largely composed of interspersed repeats, while the region
−393 to +100 is devoid of these elements (data not shown), although
it does contain a C-rich stretch (bp +37 to +84) that is partially
conserved between species (Fig. 2A). MatInspector analysis identiﬁed
potential transcription factor binding sites in upstream conserved or
partially conserved regions, including an X-box (bp −49/−38) and
three GC-box-like elements (bp−84/−79,−69/−64 and−17/−12;
hereinafter termed GC-box 1, 2 and 3, respectively) (Fig. 2A).
Notably, X-boxes are target sites for RFX transcription factors, key
regulators of genes important for the assembly and maintenance of
primary cilia (Swoboda et al., 2000; Dubruille et al., 2002). GC-boxes
are target sites for Sp/KLF transcription factors including Sp1, a
ubiquitously expressed factor implicated in the activation of a very
large number of genes (Philipsen and Suske, 1999; Wierstra, 2008).
3.3. Reporter assay analysis of the proximal promoter
To identify functional regions of the promoter we made a panel of
5' deletion constructs within the context of the pGL3-Basic luciferase
reporter vector. The longest construct (−412/+36) included the
evolutionarily conserved regions identiﬁed upstream of putative TSSs
(Fig. 2). We assayed the transcriptional activity of promoter
constructs in PANC-1 and HepG2 cells, both of which express ALMS1
(Fig. 6; and Hearn et al., 2005) and represent tissues (pancreas and
liver) affected in Alström syndrome. As shown in Fig. 2B, construct
−412/+36 exhibited strong promoter activity in these cell lines.
Deletion of bp −412 to −117 had little effect on luciferase activity.
Additional deletion of bp −116 to −91, a poorly conserved region,
reduced activity by approximately 30%. Deletion of bp −90 to −57,
including GC-boxes 1 and 2, further reduced promoter activity to
∼20% of the activity of construct −412/+36. Finally, deletion of bp
−56 to−33, including the conserved X-box, further reduced activity
to ∼5% of the activity of construct −412/+36 (Fig. 2B). These data
suggest that the region −116 to +36, which includes evolutionarily
conserved predicted transcription factor binding sites, is important for
basal transcription of ALMS1.ggested by cloning 5'-RACE products from pancreas, testes and liver, and by the cap-
' CAGE tag cluster (N2 tags) associated with ALMS1 is represented. x-axis, start position
s supporting each start site; asterisk, position of previously predicted TSS (Hearn et al.,
Fig. 2. Evolutionary conservation and reporter assay analysis of the ALMS1 promoter. (A) Alignment of human genomic sequence (bp −241 to +103) with equivalent sequences
from dog (C. familiaris), mouse (M. musculus) and rat (R. norvegicus). Shading represents conservation in all species. The positions of the predicted X-box and three GC-box
transcription factor binding sites (labelled 1–3) are indicated. (B) Luciferase reporter assays using constructs representing 5' deletions of the ALMS1 promoter. Cells were transiently
transfected and luciferase activity quantiﬁed 48 h post-transfection (black bars, HepG2; grey bars, PANC-1). Positions of the consensus X-box (striped shading, X) and GC-boxes 1, 2
and 3 are shown. Data represent four independent experiments; error bars denote s.d.
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To further investigate the functions of the X-box and GC-boxes 1–3
we generated reporter constructs with point mutations in these
elements. Mutations were made to speciﬁcally disrupt binding of
RFX proteins or Sp1 respectively (Fig. 3A) within the context of
the −232/+36 construct (Fig. 2B). We compared the activities of
mutant and wild-type constructs in PANC-1 cells. As shown in Fig. 3B,
mutating any of the individual GC-boxes in isolation reduced
transcriptional activity by approximately 50%. No additional effect
was observed on mutating site 1 in combination with site 2 or 3,
however, mutating sites 2 and 3 together decreased activity by ∼70%.
Mutating all three sites within the same construct decreased reporter
activity by ∼80% (Fig. 3B). In summary, these data indicate that: each
GC-box has a positive regulatory role; site 1 seems slightly less
important compared to sites 2 and 3; however, together they account
for most of the transcriptional activity of construct −232/+36.
Under the 10% FCS cell growth conditions used for the GC-box
analysis, mutations in the X-box did not have a signiﬁcant effect on
promoter activity (Fig. 3E). It has been reported that levels of ALMS1
mRNA increase in response to serum starvation (13). Since RFX
transcription factors including mammalian RFX3 regulate genes
involved in cilium assembly (Bonnafe et al., 2004), a process which isFig. 3. Reporter assay analysis of targeted mutations in GC-boxes 1–3 and X-box. (A) Sum
nucleotide sequences encompassing predicted X-box and GC-box transcription factor bindin
to 3'; mutations are underlined. (B) Luciferase assays using PANC-1 cells transfected withw
GC-boxes are shaded black. Luciferase activity is expressed relative to wild-type. (C) Quan
after serum-starvation. (D) Primary cilium assembly in serum-deprived PANC-1 cells. Ce
primary cilia visualized by immunostaining for acetylated tubulin (green), which labels c
10 µm. (E) Luciferase assays using PANC-1 cells transfected with wild-type or X-box-mut
either normal (10% FCS) or serum-starved (0.5% FCS) conditions for 48 h prior to lysis. Luc
experiments; error bars denote s.e.m.itself promoted on entry of cells into a quiescent state following
serum-starvation, we asked if the X-box mediates upregulation of
ALMS1 following serum deprivation. We used PANC-1 cells, which
show marked serum-dependence of cell growth (Giehl et al., 2000).
We ﬁrst conﬁrmed that serum deprivation for 48–72 h increased
levels of ALMS1mRNA and induced assembly of primary cilia in these
cells (Fig. 3C, D); the latter ﬁnding has also been independently
reported (Nielsen et al., 2008). Under these conditions, reporter
assays showed that mutations in the X-box reduced transcriptional
activity of the reporter gene by ∼60% (Fig. 3E). This strongly implies
that the X-box is required for transcription of ALMS1 in serum-
starved conditions.
3.5. EMSA analysis of X-box and GC-box-binding proteins
To investigate the protein-binding properties of the X-box and GC-
boxes 1–3, we performed EMSAs with duplex oligonucleotide probes
spanning each site. As shown in Fig. 4A, probe −23/−8 (containing
GC-box 3) formed several complexes with PANC-1 nuclear proteins.
The formation of three of these complexes was competed by including
an excess of unlabelled probe (Fig. 4A). Preincubation with Sp1
antibody lessened the intensity of the uppermost of these three bands
and gave rise to a further retarded (“supershifted”) band (Fig. 4A),mary of point mutations made in luciferase reporter construct −232/+36. Wild-type
g sites (shaded) are shown above corresponding mutant sequences. All sequences are 5'
ild-type or GC-box-mutant promoter constructs. GC-boxes are labelled 1 to 3; mutant
titative RT-PCR analysis of endogenous ALMS1 expression in PANC-1 cells before and
lls were incubated in growth medium containing either 10% or 0.5% FCS for 72 h and
iliary axonemes and centrioles. Nuclear DNA was stained with DAPI (blue). Size bar,
ant promoter constructs. The mutant X-box is shaded black. Cells were incubated in
iferase activity is expressed relative to wild-type. All data are from three independent
Fig. 4. EMSA analysis of GC-box 3 and X-box. (A) Electrophoretic mobility shift assay with PANC-1 nuclear extract and probe−23/−8, containing GC-box 3. Positions of the protein-
DNA complex with the lowest mobility (lane 2, arrow) and the complex supershifted by Sp1 antibody (lane 4, S) are indicated. Fifty-fold excess unlabelled probe was used as
competitor (lane 3). NE, nuclear extract. (B) EMSA with in vitro translated (IVT) RFX1 and probe−56/−33, containing the conserved X-box at bp−49 to−38. Positions of protein-
DNA complexes (lane 2, arrows) and complexes supershifted by RFX1 antibody (lane 3, S) are indicated. 100-fold excess unlabelled wild-type (w) or mutant (m) probe was used as
competitor, as indicated. (C) EMSA with HeLa nuclear extract and either wild-type or mutant probe −56/−33. Positions of two low-mobility complexes termed LMC1 and LMC2
(lane 2), and complexes supershifted by RFX1 antibody (lane 3, S1) and RFX2 antibody (lane 4, S2), are indicated. Fifty-fold excess unlabelled wild-type or mutant probe was used as
competitor, as indicated.
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bands were unaltered by Sp1 antibody, suggesting that they represent
binding of other factors. Probes encompassing GC-boxes 1 and 2 also
formed complexes with PANC-1 nuclear proteins, however the
formation or mobility of these complexes was not altered by Sp1
antibody (data not shown), suggesting that they also represent the
binding of other factors, which remain uncharacterised.
To investigate if RFX proteins bind to the X-box at bp−49 to−38,
we ﬁrst performed an EMSA with in vitro transcribed and translated
(IVT) RFX1, a prototypical member of the RFX family. As shown in
Fig. 4B, a probe containing the X-box (probe−56/−33) formed three
complexes with IVT-RFX1, all of which were retarded by incubation
with RFX1 antibody (Fig. 4B, lane 3). Formation of complexes was also
competed by excess unlabelled wild-type, but not mutant, probe
(Fig. 4B, lanes 4 and 5 respectively).
To test for interaction of endogenous RFX proteins with probe
−56/−33 we performed EMSAs with nuclear extract from HeLa
cells, which are known to express RFX1, 2 and 3 (Iwama et al., 1999).
Of the proteins encoded by the seven known mammalian RFX
genes (RFX1–7), RFX1–3 are the most closely related to Caenorhabditis
elegans DAF-19, a RFX protein that regulates genes of the ciliogenic
pathway (Emery et al., 1996; Swoboda et al., 2000; Aftab et al., 2008). As
shown in Fig. 4C (lane 2), probe −56/−33 formed several complexes
with HeLa nuclear proteins. RFX1 antibody supershifted the two upper-
most complexes (Fig. 4C, lane 3), indicating the presence of RFX1 in
these complexes. We termed these two low-mobility complexes
LMC1 (upper band) and LMC2 (lower band). LMC2 was abolished by
inclusion of anti-RFX2 antibody, possibly yielding a retarded complex
co-migrating with LMC1 (Fig. 4C, compare lanes 2 and 4). It is unclear
whether anti-RFX2 antibody disrupted the formation of LMC1, although
clearly it did not supershift this complex (compared to the effect of RFX1antibody). These results are consistent with LMC1 representing RFX1
homodimers, and with LMC2 containing RFX2 and possibly represent-
ing RFX1/RFX2 heterodimers, similar to previous reports (Reith et al.,
1994; Iwama et al., 1999). We did not investigate binding of RFX3 by
this approach since we were unable to demonstrate immunoreactivity
of an RFX3 antibody. Formation of LMC1 and LMC2 was competed by
unlabelled wild-type, but not mutant, probe (Fig. 4C, lanes 5 and 6
respectively), and neither complex formed with labelled mutant probe
(Fig. 4C, lane 7), supporting the speciﬁcity of binding. In summary, these
data indicate that RFX1 and RFX2 can both bind to the X-box in probe
−56/−33.
3.6. Chromatin immunoprecipitation analysis of RFX1 and RFX2 binding
to the ALMS1 promoter
To determine if RFX1 and RFX2 bind to the ALMS1 promoter in vivo,
we employed ChIP. We chose to analyse serum-deprived PANC-1
cells, since our reporter assays suggested that RFX proteins activate
ALMS1 transcription in these cells/conditions (Fig. 3E). qPCR analysis
showed that genomic DNA fragments containing the ALMS1 proximal
promoter were highly enriched in anti-RFX1 ChIP fractions, compared
to IgG negative control fractions (Fig. 5A). Levels of enrichment
obtained with anti-RFX2 were much lower than those obtained with
anti-RFX1, though still appeared signiﬁcant (Fig. 5B). Neither
antibody yielded signiﬁcant enrichment of a negative control region
(Fig. 5C). These results indicate that RFX1 and RFX2 bind to the ALMS1
promoter in vivo. The lower level of enrichment obtained with anti-
RFX2 may be due, at least in part, to antibody-related limitations. We
have been unable to detect endogenous RFX2 on immunoblots,
although the antibody does detect exogenous, overexpressed RFX2
(data not shown).
Fig. 5. Chromatin immunoprecipitation analysis of RFX1 and RFX2 binding to the ALMS1 proximal promoter. PANC-1 cells were incubated in growth medium containing 0.5% FCS for
48 h prior to analysis. (A,B) qPCR analysis of anti-RFX1 (A), anti-RFX2 (B) and IgG ChIP fractions with a Taqman assay encompassing the evolutionarily conserved X-box within the
ALMS1 promoter. Note the differing scales of the y-axes. (C) qPCR analysis of anti-RFX1, anti-RFX2 and IgG ChIP fractions with a Taqman assay targeting a negative control region
upstream of GAPDH. ChIP assays were performed with 2 or 4 µg of anti-RFX1, and with 2, 4 or 8 µg of anti-RFX2 and IgG, as indicated. DNA recovery is expressed as percentage of
input (mean±s.d. from triplicate qPCR assays).
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downregulates ALMS1 expression in serum-starved cells
To further examine the role of RFX transcription factors in regu-
lating ALMS1 we abrogated their expression by RNA interference. We
targeted RFX1, 2 or 3 in PANC-1 cells and conﬁrmed RFX transcript
depletion by qRT-PCR (Fig. 6A). We also conﬁrmed depletion of RFX1
protein by immunoblot analysis (Fig. 6B). Due to antibody-related
limitations (see above)wewereunable tomonitor RFX2orRFX3protein
depletion.Under normal growth conditions (10% serum), knockdownof
RFX transcripts did not have a signiﬁcant effect on ALMS1mRNA levels,
relative to cells transfected with a negative control siRNA (Fig. 6C).
However, under serum-starved conditions, knockdown of RFX1, 2 or 3
reduced ALMS1 mRNA levels by approximately 40–50% (Fig. 6D). As a
control, we also quantiﬁed levels of LaminmRNA in these cells (Fig. 6E).
Lamin expression was not altered by RFX siRNAs, suggesting that the
observed decrease in ALMS1mRNAwas not the result of a general effect.
Thesedata are consistentwith our promoter reporter assays, inwhichX-
box mutations decreased ALMS1 promoter activity only in serum-
starved cells (Fig. 3E), and further imply that RFXproteins, acting via the
X-box, activate ALMS1 transcription following serum starvation.
4. Discussion
Understanding why ALMS1 expression varies in different contexts
requires identiﬁcation and investigation of the promoter region
regulating its transcription. Cloning 5'-RACE products from three
different tissues, combined with data from the CAGE project (Kawaji
et al., 2006), suggests that transcription of ALMS1 is initiated at
numerous sites within a ∼70 base pair region. This region contains thepreviously predicted start of exon 1 and is therefore consistent with
the reported gene structure (Collin et al., 2002; Hearn et al., 2002). The
genomic context of this region indicates that the ALMS1 promoter
belongs to the TATA-less, CpG island-associated class of mammalian
promoters. This type of promoter typically containsmultiple GC-boxes
and has a broad TSS distribution (∼100 bp), in contrast to the tightly
deﬁned TSSs of most TATA-containing promoters (Carninci et al.,
2006). Taken together, the CAGE and RACE data support a broad TSS
distribution for ALMS1, yet the RACE data for liver and pancreas
suggest tightly deﬁned TSSs in these particular tissues. CAGE data also
suggest two downstream TSS clusters in exon 1. Recent data suggest
that many CAGE tags mapped to annotated ﬁrst exons are derived
from promoter-associated short RNAs (PASRs; Kapranov et al., 2007;
Fejes-Toth et al., 2009). These b200 nt RNAs are unlikely to be
represented in the cDNAs we used for RACE due to selection for N200
nt synthesis products during cDNA preparation. PASRs may be capped
post-transcriptional processing products of longer mRNAs, or inde-
pendent transcription products from promoters that also generate
long mRNAs (Fejes-Toth et al., 2009). Therefore, the question of
whether downstream CAGE tag clusters represent processing
products or usage of alternative ALMS1 promoters requires further
investigation.
Reporter assays using a series of 5' deletion constructs suggest
that elements important for basal ALMS1 transcription lie between
bp −116 and +36, relative to the liver TSS deﬁned by RACE. We
did not analyse the role of sequences downstream of position +36
and therefore have not excluded the possibility that the proximal
promoter extends downstream of this position. Nevertheless, we
have identiﬁed several elements between bp −116 and +36 that
signiﬁcantly inﬂuence transcriptional activity in reporter assays. Of
Fig. 6. Effect of siRNA-mediated knockdown of RFX transcripts on ALMS1 expression. (A) qRT-PCR analysis of RFX gene transcript levels in PANC-1 cells treated with siRNAs targeting
RFX1, RFX2 or RFX3. Each gray bar represents the level of the indicated RFX transcript in cells treated with the corresponding RFX siRNA, normalised to the level in cells treated with a
negative control siRNA (targeting Lamin; white bars). Data represent mean±s.e.m. from three independent experiments. (B) Immunoblot analysis of RFX1 protein expression in
siRNA-treated PANC-1 cells. β-actin was used as a loading control. (C, D) qRT-PCR analysis of ALMS1 expression in cells treated with RFX siRNAs under either normal (C) or serum-
starved (D) growth conditions; results were normalised to the expression level in cells treated with Lamin-directed siRNA. Data are from three independent experiments; error bars
denote s.e.m. (E). qRT-PCR analysis of LaminmRNA levels in cells treated with RFX or Lamin siRNAs. Results (mean±s.d. from two independent experiments) were normalized to the
level in mock-transfected cells.
27T.L. Purvis et al. / Gene 460 (2010) 20–29three GC-box-like elements analysed in this region, EMSAs indicate
that Sp1 binds to the most proximal, GC-box 3. Mutation of this
conserved site signiﬁcantly reduced promoter activity, consistent
with an activatory role for Sp1. Notably, mutation of either of the two
upstream GC-box-like elements also signiﬁcantly reduced pro-
moter activity, however EMSAs suggest that other, unidentiﬁed
factors bind to these elements. Candidates include other members of
the Sp/KLF family, e.g. Sp3, Sp4, KLF9 and KLF11 (Philipsen and
Suske, 1999).
The promoter also contains an evolutionarily conserved X-box,
suggesting regulation by RFX transcription factors. These factors are
characterisedbya conservedwinged-helixDNA-bindingdomain (Emery
et al., 1996; Gajiwala et al., 2000). The sole RFX gene in C. elegans, daf-19,
and one of the two known Drosophila RFX genes, dRfx, regulate genes
involved in the assembly, maintenance and/or function of primary cilia
(Swoboda et al., 2000; Haycraft et al., 2001; Dubruille et al., 2002;
Eﬁmenko et al., 2005; Laurencon et al., 2007). C. elegans genes whose
human orthologs are mutated in the ciliopathy Bardet–Biedl syndrome
are thought to be regulated by DAF-19 (Ansley et al., 2003). Of the
products of the seven known mammalian RFX genes (RFX1–7), RFX1, 2
and 3 are the most similar to DAF-19 at the amino acid sequence level
(Emery et al., 1996; Aftab et al., 2008) and notably RFX3-deﬁcient mice
have defective cilia, indicating conserved ciliogenic functions for this
protein in mammals (Bonnafe et al., 2004; Baas et al., 2006; Ait-Lounis
et al., 2007). With the exception of RFX5, which regulates MHC II genes
(Reith andMach, 2001), the functions of the remainingmammalian RFX
proteins are less clear. It is notable however that RFX1 and RFX2 have
similar functional domains andDNA-binding speciﬁcities to RFX3 (Reith
et al., 1994; Aftab et al., 2008), suggesting that they also activate genes of
the ciliogenic pathway (Bonnafe et al., 2004).Binding of RFX proteins to the X-box in the ALMS1 promoter
was supported by EMSAs, both with nuclear extracts and in vitro
synthesized RFX1, and by ChIP. Furthermore, our reporter assay and
RNAi data implicate these factors, acting through the X-box, in the up-
regulation of ALMS1 following serum-starvation (Yabuta et al., 2006).
Since serum-starvation promotes primary cilium formation, and
RFX family members activate genes of the ciliogenic pathway, these
ﬁndings are consistent with a speciﬁc role for ALMS1 in cilium
formation, maintenance and/or function (Hearn et al., 2005; Graser
et al., 2007; Li et al., 2007). Interestingly, a transient ciliated phase in
differentiating human preadipocytes has recently been described
(Marion et al., 2009). We speculate that a similar transition in 3 T3-L1
preadipocytes (Marion et al., 2009)may explain the reduction inAlms1
expression observed during differentiation of these cells (Romano
et al., 2008), although the ciliated status of 3 T3-L1 cells throughout
differentiation remains to be fully characterised. We also note that
ALMS1 expression is not restricted to ciliated cells, suggesting that the
protein has additional functions.
Our ChIP data indicate that RFX1 and RFX2 bind to the ALMS1
promoter in vivo. This is consistent with our EMSA results, which
suggest that both RFX1 homodimers and RFX1/RFX2heterodimers are
able to interact with the X-box in vitro. Together with the RNAi data,
these ﬁndings support the notion that RFX1 and RFX2 are directly
involved in regulating ALMS1 transcription. It remains to be deter-
mined if RFX3 (and/or RFX4–7, whose DNA-binding domains share
less sequence similarity with DAF-19; Emery et al., 1996; Aftab et al.,
2008) also interact with the ALMS1 X-box. Interestingly, regulation by
RFX family members may provide an explanation for the strong
expression of ALMS1 in testis (Collin et al., 2002; Hearn et al., 2002)
since these factors (in particular RFX2) show elevated expression in
28 T.L. Purvis et al. / Gene 460 (2010) 20–29testis and have been implicated in activating the transcription of
several testis-expressed genes including Spag6, which encodes a
component of the axoneme of the sperm ﬂagellum (Reith et al., 1994;
Wolfe et al., 2004; Horvath et al., 2009; Kistler et al., 2009). Also of
note, both RFX1 and RFX2 are thought to contain auto-regulatory
domains that inhibit transcriptional activation, implying that context-
dependent transcriptional activation by these factors is mediated by
relief of the inhibitory function, possibly via interactions with other
factors (Katan et al., 1997; Horvath et al., 2009). Understanding this
mechanism could therefore provide further insight into the context-
dependent expression of ALMS1.
In summary, our data provide the ﬁrst analysis of the ALMS1
proximal promoter. The results predict variable TSSs for exon 1, suggest
that Sp1 is important for basal ALMS1 transcription, and that RFX
proteins activate ALMS1 transcription during serum starvation-induced
growth arrest, most likely as part of the ciliogenic program.
Acknowledgments
This work was funded by the British Heart Foundation (project
grant PG/04/020). We are also grateful for support from the
Leverhulme Trust and Diabetes UK. NH acknowledges support from
the NIHRManchester Biomedical Research Centre. We thank Zijie Sun
for RFX expression constructs.
References
Aftab, S., Semenec, L., Chu, J.S., Chen, N., 2008. Identiﬁcation and characterization of
novel human tissue-speciﬁc RFX transcription factors. BMC Evol Biol 8, 226.
Ait-Lounis, A., Baas, D., Barras, E., Benadiba, C., Charollais, A., Nlend Nlend, R.,
Liegeois, D., Meda, P., Durand, B., Reith, W., 2007. Novel function of the ciliogenic
transcription factor RFX3 in development of the endocrine pancreas. Diabetes 56,
950–959.
Alstrom, C.H., Hallgren, B., Nilsson, L.B., Asander, H., 1959. Retinal degeneration combined
with obesity, diabetes mellitus and neurogenous deafness: a speciﬁc syndrome (not
hitherto described) distinct from the Laurence–Moon–Bardet–Biedl syndrome: a
clinical, endocrinological and genetic examination based on a large pedigree. Acta
Psychiatr Neurol Scand 34, 1–35.
Andersen, J.S., Wilkinson, C.J., Mayor, T., Mortensen, P., Nigg, E.A., Mann, M., 2003.
Proteomic characterization of the human centrosome by protein correlation proﬁling.
Nature 426, 570–574.
Ansley, S.J., Badano, J.L., Blacque, O.E., Hill, J., Hoskins, B.E., Leitch, C.C., Kim, J.C., Ross, A.J.,
Eichers, E.R., Teslovich, T.M., Mah, A.K., Johnsen, R.C., Cavender, J.C., Lewis, R.A.,
Leroux, M.R., Beales, P.L., Katsanis, N., 2003. Basal body dysfunction is a likely cause
of pleiotropic Bardet–Biedl syndrome. Nature 425, 628–633.
Baas, D., Meiniel, A., Benadiba, C., Bonnafe, E., Meiniel, O., Reith, W., Durand, B., 2006. A
deﬁciency in RFX3 causes hydrocephalus associated with abnormal differentiation
of ependymal cells. Eur J Neurosci 24, 1020–1030.
Badano, J.L., Mitsuma, N., Beales, P.L., Katsanis, N., 2006. The ciliopathies: an emerging
class of human genetic disorders. Annu Rev Genomics Hum Genet 7, 125–148.
Bonnafe, E., Touka, M., AitLounis, A., Baas, D., Barras, E., Ucla, C., Moreau, A., Flamant, F.,
Dubruille, R., Couble, P., Collignon, J., Durand, B., Reith, W., 2004. The transcription
factor RFX3 directs nodal cilium development and left–right asymmetry speciﬁ-
cation. Mol Cell Biol 24, 4417–4427.
Carninci, P., Sandelin, A., Lenhard, B., Katayama, S., Shimokawa, K., Ponjavic, J., Semple, C.A.,
Taylor, M.S., Engstrom, P.G., Frith, M.C., Forrest, A.R., Alkema, W.B., Tan, S.L., Plessy, C.,
Kodzius, R., Ravasi, T., Kasukawa, T., Fukuda, S., Kanamori-Katayama, M., Kitazume, Y.,
Kawaji, H., Kai, C., Nakamura, M., Konno, H., Nakano, K., Mottagui-Tabar, S., Arner, P.,
Chesi, A., Gustincich, S., Persichetti, F., Suzuki, H., Grimmond, S.M.,Wells, C.A., Orlando,
V.,Wahlestedt, C., Liu, E.T.,Harbers,M., Kawai, J., Bajic, V.B.,Hume,D.A.,Hayashizaki, Y.,
2006. Genome-wide analysis ofmammalianpromoter architecture and evolution. Nat
Genet 38, 626–635.
Collin,G.B., Cyr, E., Bronson,R.,Marshall, J.D., Gifford, E.J., Hicks,W.,Murray, S.A., Zheng,Q.Y.,
Smith,R.S., Nishina, P.M., Naggert, J.K., 2005.Alms1-disruptedmice recapitulatehuman
Alstrom syndrome. Hum Mol Genet 14, 2323–2333.
Collin, G.B., Marshall, J.D., Ikeda, A., So, W.V., Russell-Eggitt, I., Maffei, P., Beck, S.,
Boerkoel, C.F., Sicolo, N., Martin, M., Nishina, P.M., Naggert, J.K., 2002. Mutations in
ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alstrom
syndrome. Nat Genet 31, 74–78.
Dubruille, R., Laurencon, A., Vandaele, C., Shishido, E., Coulon-Bublex, M., Swoboda, P.,
Couble, P., Kernan, M., Durand, B., 2002. Drosophila regulatory factor X is necessary
for ciliated sensory neuron differentiation. Development 129, 5487–5498.
Eﬁmenko, E., Bubb, K., Mak, H.Y., Holzman, T., Leroux, M.R., Ruvkun, G., Thomas, J.H.,
Swoboda, P., 2005. Analysis of xbx genes in C. elegans. Development 132, 1923–1934.
Emery, P., Durand, B.,Mach, B., Reith,W., 1996. RFXproteins, a novel family ofDNAbinding
proteins conserved in the eukaryotic kingdom. Nucleic Acids Res 24, 803–807.
Fejes-Toth, K., Sotirova, V., Sachidanandam, R., Assaf, G., Hannon, G.J., Kapranov, P., Foissac,
S., Willingham, A.T., Duttagupta, R., Dumais, E., Gingeras, T.R., 2009. Post-transcrip-tional processinggenerates adiversity of5'-modiﬁed longand shortRNAs.Nature 457,
1028–1032.
Gajiwala, K.S., Chen, H., Cornille, F., Roques, B.P., Reith, W., Mach, B., Burley, S.K., 2000.
Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding.
Nature 403, 916–921.
Genter, M.B., Van Veldhoven, P.P., Jegga, A.G., Sakthivel, B., Kong, S., Stanley, K., Witte, D.P.,
Ebert, C.L., Aronow,B.J., 2003.Microarray-baseddiscoveryof highlyexpressedolfactory
mucosal genes: potential roles in the various functions of the olfactory system. Physiol
Genomics 16, 67–81.
Giehl, K., Skripczynski, B., Mansard, A., Menke, A., Gierschik, P., 2000. Growth factor-
dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic
carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation
and cell migration. Oncogene 19, 2930–2942.
Graser, S., Stierhof, Y.D., Lavoie, S.B., Gassner, O.S., Lamla, S., Le Clech, M., Nigg, E.A.,
2007. Cep164, a novel centriole appendage protein required for primary cilium
formation. J Cell Biol 179, 321–330.
Haycraft, C.J., Swoboda, P., Taulman, P.D., Thomas, J.H., Yoder, B.K., 2001. The C. elegans
homolog of the murine cystic kidney disease gene Tg737 functions in a ciliogenic
pathway and is disrupted in osm-5 mutant worms. Development 128, 1493–1505.
Hearn, T., Renforth, G.L., Spalluto, C., Hanley, N.A., Piper, K., Brickwood, S., White, C.,
Connolly, V., Taylor, J.F., Russell-Eggitt, I., Bonneau, D., Walker, M., Wilson, D.I.,
2002. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino
acids, causes Alstrom syndrome. Nat Genet 31, 79–83.
Hearn, T., Spalluto, C., Phillips, V.J., Renforth, G.L., Copin, N., Hanley, N.A., Wilson, D.I.,
2005. Subcellular localization of ALMS1 supports involvement of centrosome and
basal body dysfunction in the pathogenesis of obesity, insulin resistance, and type 2
diabetes. Diabetes 54, 1581–1587.
Horvath, G.C., Kistler, M.K., Kistler, W.S., 2009. RFX2 is a candidate downstream
ampliﬁer of A-MYB regulation in mouse spermatogenesis. BMC Dev Biol 9, 63.
Iwama, A., Pan, J., Zhang, P., Reith, W., Mach, B., Tenen, D.G., Sun, Z., 1999. Dimeric RFX
proteins contribute to the activity and lineage speciﬁcity of the interleukin-5
receptor alpha promoter through activation and repression domains. Mol Cell Biol
19, 3940–3950.
Kapranov, P., Cheng, J., Dike, S., Nix, D.A., Duttagupta, R., Willingham, A.T., Stadler, P.F.,
Hertel, J., Hackermuller, J., Hofacker, I.L., Bell, I., Cheung, E., Drenkow, J., Dumais, E.,
Patel, S., Helt, G., Ganesh, M., Ghosh, S., Piccolboni, A., Sementchenko, V., Tammana,
H., Gingeras, T.R., 2007. RNA maps reveal new RNA classes and a possible function
for pervasive transcription. Science 316, 1484–1488.
Katan, Y., Agami, R., Shaul, Y., 1997. The transcriptional activation and repression
domains of RFX1, a context-dependent regulator, can mutually neutralize their
activities. Nucleic Acids Res 25, 3621–3628.
Kawaji, H., Kasukawa, T., Fukuda, S., Katayama, S., Kai, C., Kawai, J., Carninci, P., Hayashizaki,
Y., 2006. CAGE Basic/Analysis Databases: the CAGE resource for comprehensive
promoter analysis. Nucleic Acids Res 34, D632–636.
Kistler, W.S., Horvath, G.C., Dasgupta, A., Kistler, M.K., 2009. Differential expression of
Rfx1-4 during mouse spermatogenesis. Gene Expr Patterns 9, 515–519.
Laurencon, A., Dubruille, R., Eﬁmenko, E., Grenier, G., Bissett, R., Cortier, E., Rolland, V.,
Swoboda, P., Durand, B., 2007. Identiﬁcation of novel regulatory factor X (RFX)
target genes by comparative genomics in Drosophila species. Genome Biol 8, R195.
Li, G., Vega, R., Nelms, K., Gekakis, N., Goodnow, C., McNamara, P., Wu, H., Hong, N.A.,
Glynne, R., 2007. A role for Alstrom syndrome protein, alms1, in kidney ciliogenesis
and cellular quiescence. PLoS Genet 3, e8.
Marion, V., Stoetzel, C., Schlicht, D.,Messaddeq, N., Koch,M., Flori, E., Danse, J.M.,Mandel,
J.L., Dollfus, H., 2009. Transient ciliogenesis involving Bardet–Biedl syndrome
proteins is a fundamental characteristic of adipogenic differentiation. ProcNatl Acad
Sci U S A 106, 1820–1825.
Marshall, J.D., Bronson, R.T., Collin, G.B., Nordstrom, A.D., Maffei, P., Paisey, R.B., Carey,
C., Macdermott, S., Russell-Eggitt, I., Shea, S.E., Davis, J., Beck, S., Shatirishvili, G.,
Mihai, C.M., Hoeltzenbein, M., Pozzan, G.B., Hopkinson, I., Sicolo, N., Naggert, J.K.,
Nishina, P.M., 2005. New Alstrom syndrome phenotypes based on the evaluation of
182 cases. Arch Intern Med 165, 675–683.
Nielsen, S.K., Mollgard, K., Clement, C.A., Veland, I.R., Awan, A., Yoder, B.K., Novak, I.,
Christensen, S.T., 2008. Characterization of primary cilia and Hedgehog signaling
during development of the human pancreas and in human pancreatic duct cancer
cell lines. Dev Dyn 237, 2039–2052.
Philipsen, S., Suske, G., 1999. A tale of three ﬁngers: the family of mammalian Sp/XKLF
transcription factors. Nucleic Acids Res 27, 2991–3000.
Reith, W., Mach, B., 2001. The bare lymphocyte syndrome and the regulation of MHC
expression. Annu Rev Immunol 19, 331–373.
Reith, W., Ucla, C., Barras, E., Gaud, A., Durand, B., Herrero-Sanchez, C., Kobr, M., Mach,
B., 1994. RFX1, a transactivator of hepatitis B virus enhancer I, belongs to a novel
family of homodimeric and heterodimeric DNA-binding proteins. Mol Cell Biol 14,
1230–1244.
Romano, S., Milan, G., Veronese, C., Collin, G.B., Marshall, J.D., Centobene, C., Favaretto, F.,
Dal Pra, C., Scarda, A., Leandri, S., Naggert, J.K., Maffei, P., Vettor, R., 2008. Regulation
of Alstrom syndrome gene expression during adipogenesis and its relationshipwith
fat cell insulin sensitivity. Int J Mol Med 21, 731–736.
Sanchez-Elsner, T., Ramirez, J.R., Sanz-Rodriguez, F., Varela, E., Bernabeu, C., Botella, L.M.,
2004. A cross-talk between hypoxia and TGF-beta orchestrates erythropoietin gene
regulation through SP1 and Smads. J Mol Biol 336, 9–24.
Schreiber, E., Matthias, P., Muller, M.M., Schaffner, W., 1989. Rapid detection of octamer
binding proteins with “mini-extracts,” prepared from a small number of cells.
Nucleic Acids Res 17, 6419.
Shiraki, T., Kondo, S., Katayama, S.,Waki, K., Kasukawa, T., Kawaji, H., Kodzius, R.,Watahiki,
A., Nakamura, M., Arakawa, T., Fukuda, S., Sasaki, D., Podhajska, A., Harbers, M., Kawai,
J., Carninci, P., Hayashizaki, Y., 2003. Cap analysis gene expression for high-throughput
29T.L. Purvis et al. / Gene 460 (2010) 20–29analysis of transcriptional starting point and identiﬁcation of promoter usage. Proc
Natl Acad Sci U S A 100, 15776–15781.
Swoboda, P., Adler, H.T., Thomas, J.H., 2000. The RFX-type transcription factor DAF-19
regulates sensory neuron cilium formation in C. elegans. Mol Cell 5, 411–421.
Wierstra, I., 2008. Sp1: emerging roles—beyond constitutive activation of TATA-less
housekeeping genes. Biochem Biophys Res Commun 372, 1–13.Wolfe, S.A., Wilkerson, D.C., Prado, S., Grimes, S.R., 2004. Regulatory factor X2 (RFX2)
binds to the H1t/TE1 promoter element and activates transcription of the testis-
speciﬁc histone H1t gene. J Cell Biochem 91, 375–383.
Yabuta, N., Onda, H., Watanabe, M., Yoshioka, N., Nagamori, I., Funatsu, T., Toji, S., Tamai,
K., Nojima, H., 2006. Isolation and characterization of the TIGA genes, whose
transcripts are induced by growth arrest. Nucleic Acids Res 34, 4878–4892.
